Levi & Korsinsky notifies investors that it has commenced an investigation into argenx SE (NASDAQ: ARGX) concerning potential violations of the federal securities laws.
On December 20, 2023, Investor's Business Daily reported that argenx 's "stock crashed early Wednesday after its treatment for an autoimmune disease that causes skin blisters flopped in a Phase 3 study." Based on this news, shares of the Company's stock were down by more than 25% in intraday trading on the same day.
If you suffered a loss on your argenx securities and would like to explore a potential recovery under the federal securities laws, submit to us or contact Joseph E. Levi, Esq. via email at [email protected] or call 212-363-7500 to speak to our team of experienced shareholder advocates.
Please provide your address so we can contact you about your case if eligible.






Input your stock purchases and sales












Connect with SnapTrade to let us the stocks you own. This is an optional step to keep you. informed about class action litigation.
✓ Fast: takes less than a min
✓ We do not create an attorney-client relationship
✓ Your information is confidential & secure





